| April 1, 2027 |
TLSA |
A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA) |
Trial Milestone |
Phase 2 |
| April 2, 2027 |
REGN |
Study of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult Participants With End-Stage Kidney Disease on Hemodialysis |
Trial Milestone |
Phase 1 |
| April 7, 2027 |
JNJ |
A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma |
Trial Milestone |
Phase 1 |
| April 7, 2027 |
NVO |
A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood of Participants With Excess Body Weight |
Trial Milestone |
Phase 1 |
| April 9, 2027 |
NVS |
Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer |
Trial Milestone |
Phase 1 |
| April 10, 2027 |
AMGN |
A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma |
Trial Milestone |
Phase 1 |
| April 12, 2027 |
NVS |
Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) |
Trial Milestone |
Phase 3 |
| April 13, 2027 |
INCY |
A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment |
Trial Milestone |
Phase 1 |
| April 14, 2027 |
BMRN |
A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMN 351 in Participants With Duchenne Muscular Dystrophy |
Trial Milestone |
Phase 1/Phase 2 |
| April 15, 2027 |
LLY |
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 ) |
Trial Milestone |
Phase 1 |
| April 15, 2027 |
ABBV |
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Ascending Doses of ABBV-1451 Infusions and Injections in Healthy Adult Participants |
Trial Milestone |
Phase 1 |
| April 15, 2027 |
SVA |
Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 3-5 Months |
Trial Milestone |
Phase 3 |
| April 15, 2027 |
SVA |
Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 6-11 Months |
Trial Milestone |
Phase 3 |
| April 15, 2027 |
IONS |
PrProfile: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ION717 |
Trial Milestone |
Phase 1/Phase 2 |
| April 15, 2027 |
XENE |
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures |
Trial Milestone |
Phase 3 |
| April 15, 2027 |
KPTI |
Selinexor and Backbone Treatments of Multiple Myeloma Patients |
Trial Milestone |
Phase 1/Phase 2 |
| April 15, 2027 |
KOD |
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK |
Trial Milestone |
Phase 3 |
| April 15, 2027 |
GKOS |
Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus |
Trial Milestone |
Phase 2 |
| April 15, 2027 |
VTVT |
Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes |
Trial Milestone |
Phase 3 |
| April 15, 2027 |
KYTX |
KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis |
Trial Milestone |
Phase 2 |
| April 15, 2027 |
MNOV |
Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS |
Trial Milestone |
Phase 2/Phase 3 |
| April 15, 2027 |
LONA |
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation |
Trial Milestone |
Phase 3 |
| April 15, 2027 |
CLYM |
A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE) |
Trial Milestone |
Phase 1 |
| April 15, 2027 |
KYMR |
A Study to Evaluate Different Oral Formulations of KT-621 |
Trial Milestone |
Phase 1 |
| April 15, 2027 |
COYA |
Study of COYA 302 for the Treatment of ALS |
Trial Milestone |
Phase 2/Phase 3 |
| April 15, 2027 |
NKTX |
A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1) |
Trial Milestone |
Phase 1/Phase 2 |
| April 19, 2027 |
AMGN |
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab) |
Trial Milestone |
Phase 3 |
| April 20, 2027 |
AZN |
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy |
Trial Milestone |
Phase 3 |
| April 21, 2027 |
SNY |
Study to Assess the Plasma Concentration of Rilzabrutinib Given as a Tablet to Adult Participants With Severe Renal Impairment Compared to Matched Participants With Normal Renal Function |
Trial Milestone |
Phase 1 |
| April 21, 2027 |
BNTX |
A Study of COVID-19 Vaccine(s) in Children and Adults |
Trial Milestone |
Phase 3 |
| April 24, 2027 |
REGN |
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma |
Trial Milestone |
Phase 4 |
| April 25, 2027 |
PFE |
A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH) |
Trial Milestone |
Phase 2 |
| April 25, 2027 |
ORMP |
A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus. |
Trial Milestone |
Phase 3 |
| April 27, 2027 |
AMGN |
A Study for the Evaluation of Efficacy and Safety of Prolia® in Participants With Glucocorticoid-induced Osteoporosis in Mainland China |
Trial Milestone |
Phase 4 |
| April 27, 2027 |
INCY |
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression |
Trial Milestone |
Phase 2 |
| April 28, 2027 |
JNJ |
A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer |
Trial Milestone |
Phase 1/Phase 2 |
| April 28, 2027 |
SNY |
Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults, Adolescents and Children on Top of Insulin Therapy (FABULINUS) |
Trial Milestone |
Phase 2 |
| April 28, 2027 |
ALNY |
A Study to Evaluate ALN-2232 in Participants With Obesity |
Trial Milestone |
Phase 1/Phase 2 |
| April 29, 2027 |
SNY |
A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis |
Trial Milestone |
Phase 4 |
| April 30, 2027 |
NVS |
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG. |
Trial Milestone |
Phase 3 |
| April 30, 2027 |
INCY |
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo |
Trial Milestone |
Phase 3 |
| April 30, 2027 |
INCY |
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms |
Trial Milestone |
Phase 1 |
| April 30, 2027 |
ARGX |
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) |
Trial Milestone |
Phase 2 |
| April 30, 2027 |
INBS |
Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Diabetic Macular Edema |
Trial Milestone |
Phase 3 |
| April 30, 2027 |
IDYA |
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma |
Trial Milestone |
Phase 2 |
| April 30, 2027 |
RLAY |
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer |
Trial Milestone |
Phase 1 |
| April 30, 2027 |
COAG |
A First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of HMB-003 in Healthy Volunteers |
Trial Milestone |
Phase 1 |
| April 30, 2027 |
RIGL |
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies |
Trial Milestone |
Phase 4 |